CANTON, Mass., July 10, 2018 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the promotion of Scott Dreyer to the position of Executive Vice President and Chief Commercial Officer, effective July 10, 2018. Mr. Dreyer brings over 25 years of commercial leadership and expertise, in both biotechnology and pharmaceutical companies.
“We’re pleased to promote Scott to serve as our Chief Commercial Officer,” commented Joe Ciaffoni, Collegium’s CEO. “Scott is a proven leader and has already had a positive impact on Collegium’s commercial organization. We look forward to his contributions to the executive team as we strive to become the leader in responsible pain management.”
Mr. Dreyer joined Collegium as Senior Vice President, Sales, Marketing and Training in January 2018. Prior to joining Collegium, Mr. Dreyer held senior commercial roles in various organizations, including serving as Senior Vice President, Sales, Marketing and Commercial Operations at The Medicines Company and Vice President and Chief Marketing Officer – US at Biogen. Mr. Dreyer began his career at Merck & Co. Inc., where he rose from an entry position as a biotechnician to Vice President, responsible for US Hospital and Oncology Sales and US Primary Care Sales. Throughout his career, Mr. Dreyer has held leadership positions that span sales, marketing, market access, commercial operations and strategic planning. Mr. Dreyer holds a Bachelor of Science (Biology) from Messiah College.
“I am thrilled to be a part of the Collegium team during this exciting time, as we build on Xtampza’s commercial momentum and continue to integrate the Nucynta franchise,” said Mr. Dreyer. “We have a portfolio of innovative and differentiated products, and I look forward to leading the commercial organization as we focus on making a difference for patients suffering from pain and our communities.”
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for patients suffering from pain and our communities.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.